BNP Paribas Financial Markets Buys New Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)

BNP Paribas Financial Markets purchased a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 468,010 shares of the company's stock, valued at approximately $5,537,000. BNP Paribas Financial Markets owned approximately 0.06% of Roivant Sciences as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. grew its position in shares of Roivant Sciences by 478.6% in the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock valued at $28,000 after purchasing an additional 1,948 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in shares of Roivant Sciences in the fourth quarter valued at approximately $39,000. GAMMA Investing LLC grew its position in shares of Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock valued at $42,000 after purchasing an additional 1,288 shares during the last quarter. PNC Financial Services Group Inc. grew its position in shares of Roivant Sciences by 27.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock valued at $84,000 after purchasing an additional 1,507 shares during the last quarter. Finally, Wells Fargo & Company MN grew its position in shares of Roivant Sciences by 84.1% in the fourth quarter. Wells Fargo & Company MN now owns 7,501 shares of the company's stock valued at $89,000 after purchasing an additional 3,426 shares during the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ROIV has been the topic of several research reports. HC Wainwright reiterated a "buy" rating and issued a $18.00 price target on shares of Roivant Sciences in a research report on Monday, April 21st. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th.

Insider Buying and Selling

In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 273,959 shares of Roivant Sciences stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $11.47, for a total value of $3,142,309.73. Following the transaction, the insider now owns 39,799,611 shares in the company, valued at $456,501,538.17. This trade represents a 0.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $10.65, for a total transaction of $1,065,000.00. Following the completion of the transaction, the chief operating officer now owns 896,869 shares in the company, valued at approximately $9,551,654.85. This trade represents a 10.03% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,223,959 shares of company stock worth $13,420,035. 7.90% of the stock is owned by insiders.

Roivant Sciences Stock Performance

NASDAQ ROIV traded up $0.05 during mid-day trading on Monday, reaching $10.84. 3,576,583 shares of the stock were exchanged, compared to its average volume of 5,584,013. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $13.06. The business's fifty day simple moving average is $10.51 and its 200 day simple moving average is $11.07. The stock has a market capitalization of $7.73 billion, a PE ratio of -72.26 and a beta of 1.23.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.